Loading

logo

Journal of Cellular Signaling

ISSN: 2692-0638

Mini Review Open Access
Volume 4 | Issue 1 | DOI: https://doi.org/10.33696/Signaling.4.087

Purinergic P2X7 Receptor as a Potential Targeted Therapy for COVID-19-associated Lung Cancer Progression

Hamidreza Zalpoor1,2, Abdullatif Akbari2, Mohsen Nabi-Afjadi3, Ali Norouzi4, Farhad Seif5,6*, Majid Pornour7,*
  • 1Shiraz Neuroscience Research Center, Shiraz University of Medical Sciences, Shiraz, Iran
  • 2Network of Immunity in Infection, Malignancy & Autoimmunity (NIIMA), Universal Scientific Education & Research Network (USERN), Tehran, Iran
  • 3Department of Biochemistry, Faculty of biological science, Tarbiat Modares University, Tehran, Iran
  • 4Dental Research Center, Faculty of Dentistry, Mazandaran University of Medical Sciences, Sari, Iran
  • 5Department of Immunology and Allergy, Academic Center for Education, Culture, and Research (ACECR), Tehran, Iran
  • 6Neuroscience Research Center, Iran University of Medical Sciences, Tehran, Iran
  • 7Department of Oncology, School of Medicine, University of Maryland, Maryland, USA
+ Affiliations - Affiliations

Corresponding Author

Farhad Seif, farhad.seif@outlook.com; Majid Pornour, ma.pornour@gmail.com

Received Date: December 06, 2022

Accepted Date: January 24, 2023

Citation:

Zalpoor H, Akbari A, Nabi-Afjadi M, Norouzi A, Seif F, Pornour M. Purinergic P2X7 Receptor as a Potential Targeted Therapy for COVID-19-associated Lung Cancer Progression. J Cell Signal. 2023;4(1):21-25.


Copyright: © 2023 Zalpoor H, et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.

Abstract

Severe acute respiratory syndrome Coronavirus 2 (SARS-CoV-2) infection is a serious threat to lung cancer patients. Hereby, we hypothesize that Coronavirus disease 2019 (COVID-19) may contribute to lung cancer progression by increasing extracellular adenosine triphosphate (ATP) levels and hyperactivating the purinergic P2X purinoceptor 7 receptor (P2X7R). Hyperactivation of P2X7R by increased extracellular ATP may stimulate multiple signaling pathways and factors such as NLRP3 inflammasome; as a result, interleukin (IL)-1β, and IL-18 pro-inflammatory cytokines are released, JNK, Rho kinase, HMGB1-RAGE, PI3K/AKT, hypoxia-inducible factor-1 alpha (HIF-1α), and ERK. NLRP3 activation may play a pivotal role in fatal cytokine storm in critically ill patients with COVID-19 and tumor progression in patients with lung cancer. Consequently, inhibiting these signaling pathways may deviate immune responses toward anti-tumoral responses, and suppress lung cancer progression and cytokine storms. Therefore, targeting P2X7R by means of oxidized ATP and anti-P2X7 monoclonal antibodies may provide promising therapeutic approaches to prevent lung cancer progression in COVID-19 patients; however, no clinical trials have yet been conducted, and their clinical efficacy remains to be elucidated.

Keywords

COVID-19, SARS-CoV-2, Lung cancer, P2X7 receptor, Cancer progression

Recommended Articles

COVID-19 Clinical Research

While the global COVID-19 pandemic has challenged the entire humanity and health systems, it also triggered researchers to urgently perform clinical trials to assess the safety and efficacy of many agents and modalities to combat COVID-19. As of April 22, over 650 clinical studies have been registered both in USA and internationally. Results from these studies are also coming at a brisk pace in this unprecedented emergency.

Uniportal VATS Lobectomy for Lung Cancer: Feasibility and Cost Effectiveness in a Single Center Experience

In last decades, video-assisted thoracic surgery (VATS) together with robotic-assisted thoracic surgery (RATS) can be considered the biggest innovation in thoracic surgery. This approach drastically changed the way of performing surgical operations, improving patient’s outcome undergoing thoracic surgery.

In silico Analysis for the Repurposing of Broad-spectrum Antiviral Drugs against Multiple Targets from SARS-CoV-2: A Molecular Docking and ADMET Approach

SARS-CoV-2 belongs to the genus Beta of the Coronaviridae family of enveloped single-stranded, positive-sense ribonucleic acid (RNA) with a genome length of 30,000bp. The virion is composed of various non-structural (RNA dependent RNA polymerase also known as RdRp) and structural proteins such as Spike (S), Nucleocapsid (N), Matrix (M), and Envelope (E) proteins.

Surgery Versus Radiation Therapy for Early-Stage Lung Cancer: Patient Selection is Crucial

Lung cancer remains the leading cause of cancer related death in the United States with mortality rates surpassing breast, prostate, brain, and colorectal cancers combined. Recent data shows that susceptibility for both men and women for developing invasive lung and bronchogenic carcinoma peak after the age of 70 years.

Beta-Sitosterol: As Immunostimulant, Antioxidant and Inhibitor of SARS-CoV-2 Spike Glycoprotein

This article is an extension to our recently published article in Asian Journal of Pharmaceutical and Clinical Research, entitled “Β-Sitosterol: Isolation from Muntingia Calabura Linn. Bark Extract, Structural Elucidation, and Molecular Docking Studies as Potential Inhibitor of SARSCoV-2 Mpro (COVID-19)”[1].

Full Text
Cite
Download PDF
Author Information X

About Scientific Archives

Scientific Archives is a global publisher initiated with the mission of ensuring equal opportunity for accessing science to research community all over the world. Spreading research findings with great relevance to all channels without any barrier is our goal. We want to overcome the challenges of Open Access with ensured quality and transparency.

Read More